Ichor Medical Systems Inc. is a private biotechnology firm established in San Diego in 1994. The company is focused on creating products that utilize electroporation to improve the intracellular delivery of nucleic acid-based drugs, antigens for vaccines, or antibodies for passive immunity. These treatments aim to combat debilitating or life-threatening illnesses. Ichor's unique TriGrid Delivery System is the first fully automated system for electroporation-mediated in vivo nucleic acid administration. This system allows for complete control over the site of injection, electrode placement, agent administration rate, and electroporation delivery timing. Consequently, TriGrid enables the practical application of electroporation in a way that supports the development and commercialization of nucleic acid-based therapies.

Tags

Infectious Diseases

Digestive System Disorders

DNA vaccine

Therapeutic vaccine

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2

Top 5 Drug Type	Count

DNA vaccine	2
Therapeutic vaccine	1
Prophylactic vaccine	1

Top 5 Target	Count

hantavirus M protein	1

Drugs associated with Ichor Medical Systems, Inc.

pWRG/HTN-M(co)/pWRG/PUUV-M(United States Army Medical Research and Materiel Command)

Target

hantavirus M protein

Mechanism

hantavirus M protein inhibitors

Active Org.

Ichor Medical Systems, Inc. [+1]

Originator Org.

United States Army Medical Research and Materiel Command

Active Indication

Hemorrhagic Fevers, Viral

Inactive Indication

Hemorrhagic Fever With Renal Syndrome

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

JNJ-64300535

Target-

Mechanism

Immunostimulants

Active Org.

Janssen Research & Development LLC [+1]

Originator Org.

Ichor Medical Systems, Inc.

Active Indication

Hepatitis B, Chronic [+1]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

pSG2.HIVconsv(University of Oxford)

Target-

Mechanism

Immunostimulants

Active Org.

University of Oxford

Originator Org.

University of Oxford

Active Indication

HIV Infections

Inactive Indication

Acquired Immunodeficiency Syndrome

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Ichor Medical Systems, Inc.

NCT04357821 / Active, not recruitingPhase 1/2IIT

Combinatorial Therapy With a Therapeutic Conserved Element DNA Vaccine, MVA Vaccine Boost, TLR9 Agonist and Broadly Neutralizing Antibodies: a Proof-of-concept Study Aimed at Inducing an HIV Remission

Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption (ATI).

Start Date01 Aug 2020

Sponsor / Collaborator

The University of California, San Francisco

[+7]

NCT02116205 / CompletedPhase 2IIT

A Phase 2a Double-Blind, Dose-optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers by Electroporation for Prevention of Hemorrhagic Fever With Renal Syndrome

The purpose of this study is to compare the immune responses of two different doses (1.0 mg and 2.0 mg) and two different dosing schedules (two doses or three doses) of a mixed Hantaan virus (HTNV) and Puumala virus (PUUV) DNA vaccine in healthy participants. To maintain a blind, participants in the two-dose group will receive one dose of normal saline placebo. All of the groups will also receive a booster dose 6 months after first vaccination. The results will help to determine which dose and vaccination schedule will be best to move forward in the vaccine development process.

Start Date09 Jul 2014

Sponsor / Collaborator

U S Army Medical Research & Development Command

[+4]

NCT02099994 / CompletedPhase 1/2IIT

A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.

The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate safety and immunogenicity of vaccines focusing T cell responses on the conserved region of the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates electroporation.

Start Date01 Mar 2014

Sponsor / Collaborator

University of Oxford

[+4]

100 Clinical Results associated with Ichor Medical Systems, Inc.

0 Patents (Medical) associated with Ichor Medical Systems, Inc.

Literatures (Medical) associated with Ichor Medical Systems, Inc.

03 Jun 2018·Journal of Immunology ResearchQ3 · MEDICINE

A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges

Q3 · MEDICINE

ArticleOA

Author: Dupuy, Lesley C. ; Richards, Michelle J. ; Schmaljohn, Connie S. ; Livingston, Brian D. ; Hannaman, Drew

There remains a need for vaccines that can safely and effectively protect against the biological threat agents Venezuelan (VEEV), western (WEEV), and eastern (EEEV) equine encephalitis virus. Previously, we demonstrated that a VEEV DNA vaccine that was optimized for increased antigen expression and delivered by intramuscular (IM) electroporation (EP) elicited robust and durable virus-specific antibody responses in multiple animal species and provided complete protection against VEEV aerosol challenge in mice and nonhuman primates. Here, we performed a comparative evaluation of the immunogenicity and protective efficacy of individual optimized VEEV, WEEV, and EEEV DNA vaccines with that of a 1 : 1 : 1 mixture of these vaccines, which we have termed the 3-EEV DNA vaccine, when delivered by IM EP. The individual DNA vaccines and the 3-EEV DNA vaccine elicited robust and durable virus-specific antibody responses in mice and rabbits and completely protected mice from homologous VEEV, WEEV, and EEEV aerosol challenges. Taken together, the results from these studies demonstrate that the individual VEEV, WEEV, and EEEV DNA vaccines and the 3-EEV DNA vaccine delivered by IM EP provide an effective means of eliciting protection against lethal encephalitic alphavirus infections in a murine model and represent viable next-generation vaccine candidates that warrant further development.

01 Dec 2017·VaccineQ3 · MEDICINE

Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques

Q3 · MEDICINE

Article

Author: Gerloff, Dietlind ; Philipp, Mario ; Kumar, Nirbhay ; Hannaman, Drew ; Datta, Dibyadyuti ; Bansal, Geetha P ; Grasperge, Brooke ; Martin, Dale S ; Ellefsen, Barry

Antibodies recognizing conformational epitopes in Pfs48/45, an antigen expressed on the surface of Plasmodium falciparum gametes and zygotes, have firmly established Pfs48/45 as a promising transmission blocking vaccine (TBV) candidate. However, it has been difficult to reproducibly express Pfs48/45 in a variety of recombinant expression systems. The goal of our studies was to evaluate functional immunogenicity of Pfs48/45 using DNA vaccine format in rhesus macaques. An additional goal was to ensure that when used in combination with another malarial antigen, specific immunity to both antigens was not compromised. For testing combination vaccines, we employed Pfs25 DNA plasmids that have previously undergone evaluations in rodents and nonhuman primates. Pfs25 is expressed on the surface of parasites after fertilization and is also a lead TBV candidate. DNA plasmids based on codon-optimized sequences of Pfs48/45 and Pfs25 were administered by in vivo electroporation, followed by a final recombinant protein boost. Our studies demonstrate that Pfs48/45 encoded by DNA plasmids is capable of inducing potent transmission blocking antibody responses, and such transmission blocking immune potency of Pfs48/45 was not compromised when tested in combination with Pfs25, These findings provide the evidence in favor of further studies on Pfs48/45 and Pfs25, either alone or in combination with other known malaria vaccine candidates for developing effective vaccines capable of interrupting malaria transmission.

01 Nov 2017·Clinical and Vaccine Immunology

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA

Article

Author: Li, Shuying S. ; McElrath, M. Juliana ; Egan, Michael A. ; De Rosa, Stephen C. ; Frank, Ian ; Corey, Lawrence ; Kochar, Nidhi K. ; Tomaras, Georgia D. ; Hay, Christine M. ; Frahm, Nicole ; Gottardo, Raphael ; Hannaman, Drew ; Eldridge, John H. ; Morris, Daryl ; Finak, Greg ; Wilson, Gregory J. ; Sobieszczyk, Magdalena E. ; Allen, Mary ; Gilbert, Peter B. ; Xu, Rong ; Ota-Setlik, Ayuko ; Clarke, David K. ; Cohen, Kristen W. ; Elizaga, Marnie ; Tieu, Hong-Van

ABSTRACT The HIV Vaccine Trials Network (HVTN) 087 vaccine trial assessed the effect of increasing doses of pIL-12 (interleukin-12 delivered as plasmid DNA) adjuvant on the immunogenicity of an HIV-1 multiantigen (MAG) DNA vaccine delivered by electroporation and boosted with a vaccine comprising an attenuated vesicular stomatitis virus expressing HIV-1 Gag (VSV-Gag). We randomized 100 healthy adults to receive placebo or 3 mg HIV-MAG DNA vaccine (ProfectusVax HIV-1 gag / pol or ProfectusVax nef / tat / vif , env ) coadministered with pIL-12 at 0, 250, 1,000, or 1,500 μg intramuscularly by electroporation at 0, 1, and 3 months followed by intramuscular inoculation with 3.4 × 10 7 PFU VSV-Gag vaccine at 6 months. Immune responses were assessed after the prime and boost and 6 months after the last vaccination. High-dose pIL-12 increased the magnitude of CD8 + T-cell responses postboost compared to no pIL-12 ( P = 0.02), while CD4 + T-cell responses after the prime were higher in the absence of pIL-12 than with low- and medium-dose pIL-12 ( P ≤ 0.05). The VSV boost increased Gag-specific CD4 + and CD8 + T-cell responses in all groups ( P < 0.001 for CD4 + T cells), inducing a median of four Gag epitopes in responders. Six to 9 months after the boost, responses decreased in magnitude, but CD8 + T-cell response rates were maintained. The addition of a DNA prime dramatically improved responses to the VSV vaccine tested previously in the HVTN 090 trial, leading to broad epitope targeting and maintained CD8 + T-cell response rates at early memory. The addition of high-dose pIL-12 given with a DNA prime by electroporation and boosted with VSV-Gag increased the CD8 + T-cell responses but decreased the CD4 + responses. This approach may be advantageous in reshaping the T-cell responses to a variety of chronic infections or tumors. (This study has been registered at ClinicalTrials.gov under registration no. NCT01578889.)

News (Medical) associated with Ichor Medical Systems, Inc.

31 Jan 2024

·www.fiercebiotech.com

CRO Ichor Life Sciences launches clinical trial services unit

As part of the rollout, Ichor announced that Lisa Sonneborn was named president of the new trial services unit. Ichor Life Sciences, a CRO based in upstate New York, has launched a clinical trial services unit to serve clients in preclinical studies through late-stage trials and regulatory approval. Dubbed Ichor Clinical, the new branch offers clients in the preclinical arena protein, pharmacology, discovery and consulting services, the company said in a January 14 press release. As part of the rollout, Ichor announced that Lisa Sonneborn was named president of the new trial services unit. Sonneborn was founder and chief executive of Clarity Clinical Research, which was acquired by the site management giant Velocity in 2021. Ichor Life Sciences, which rebranded itself from Ichor Therapeutics in 2021, is not connected to San Diego-based biotech Ichor Medical Systems.

AcquisitionExecutive ChangeClinical Study

22 Jun 2023

·www.prnewswire.com

Global Cancer Vaccine Partnering Terms and Agreements Analysis Report/Directory 2023: Access Over 350 Cancer Vaccine Deals - Disclosed Headlines, Upfronts, Milestones and Royalties

DUBLIN, June 22, 2023 /PRNewswire/ -- The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Cancer Vaccine Partnering Terms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 350 cancer vaccine deals. Trends in cancer vaccine partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer vaccine partnering contract documents Top cancer vaccine deals by value This report provides details of the latest cancer vaccine agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review cancer vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering cancer vaccine partnering deals. The report presents financial deal term values for cancer vaccine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the cancer vaccine partnering field; both the leading deal values and most active cancer vaccine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 350 online deal records of actual cancer vaccine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of cancer vaccine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading cancer vaccine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer vaccine dealmaking with a brief summary followed by a comprehensive listing of cancer vaccine deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since Jan 2010. The chapter is organized by specific cancer vaccine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by cancer vaccine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products. Key benefits In-depth understanding of cancer vaccine deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual cancer vaccine contracts entered into by leading biopharma companies Identify most active cancer vaccine dealmakers since 2010 Insight into terms included in a cancer vaccine partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies In Global Cancer Vaccine Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sale sand payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned 2A 3D Medicines A*STAR Bioprocessing Technology Institute Aura Biosciences Averion AV Therapeutics Beth Israel Deaconess Medical Center BGI CureLab Oncology CureVac Cyplasin Biomedical CYTLIMIC Daiichi Sankyo Dainippon Sumitomo Pharma Dalton Pharma Services Exiqon ExpreS2ion Biotechnologies Federal Ministry of Education and Research (BMBF) Flaskworks Georgia Health Sciences University GeoVax German Cancer Research Center Hookipa Pharma Human Vaccines Project iBio Icahn School of Medicine at Mount Sinai Ichor Medical Systems Leukaemia & Lymphoma Research LG Life Sciences Ligand Pharmaceuticals Massachusetts Life Sciences Center Mayo Clinic National Research Council Canada National Surgical Adjuvant Breast and Bowel Project OncoQR OncoSec Medical Oncotherapy Science PsiOxus Therapeutics Pulmotec PX Biosolutions Qiagen Radboud University Nijmegen Medical Centre Selecta Biosciences Selexis Sellas Clinicals Holding Seres Therapeutics Telormedix Teva Pharmaceutical Industries VGX International Vinnova ViroMed Vivalis VLP Therapeutics VLST Corporation Y-mAbs Therapeutics Yale University Yamaguchi University For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Vaccine

06 Aug 2007

·www.biospace.com

Navy Partners with Ichor Medical Systems, Inc. to Develop a Vaccine for Anthrax and Plague

SAN DIEGO--(BUSINESS WIRE)--Ichor Medical Systems, whose advanced electroporation system is being used worldwide to increase the effectiveness of DNA drug and vaccine delivery, has been awarded a two-year contract valued at over $2.3 million by the Defense Threat Reduction Agency (DTRA). Ichor will assist the Biological Defense Research Directorate (BDRD) of the Naval Medical Research Center (NMRC) in Rockville, Maryland in the development of a DNA vaccine for anthrax and plague.

Vaccine

100 Deals associated with Ichor Medical Systems, Inc.

100 Translational Medicine associated with Ichor Medical Systems, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

pWRG/HTN-M(co)/pWRG/PUUV-M(United States Army Medical Research and Materiel Command) ( hantavirus M protein )	Hemorrhagic Fevers, Viral More	Phase 2
JNJ-64300535	Hepatitis B More	Phase 1
pNGVL-4a-CRT/E7 DNA vaccine(Ichor Medical Systems, Inc.) ( HPV E7 )	Head and Neck Neoplasms More	Discontinued
Ad35-GRIN/ENV ( Envelope (E) protein x GAG )	Acquired Immunodeficiency Syndrome More	Pending
Venezuelan equine encephalitis virus vaccine(United States Army Medical Research and Materiel Command)	Encephalomyelitis, Venezuelan Equine More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis